A Randomized, Placebo-Controlled Trial of Modafinil for Methamphetamine Dependence
NCT ID: NCT01354470
Last Updated: 2013-07-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
72 participants
INTERVENTIONAL
2011-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Modafinil vs Placebo for the Treatment of Methamphetamine Dependence
NCT00469508
A Pilot Trial of Modafinil for Treatment of Methamphetamine Dependence
NCT00538655
Phase 2, Multi-Center Trial of Modafinil for Methamphetamine Dependence
NCT00520286
Trial of Modafinil for Methamphetamine Dependence
NCT00123370
Modafinil for Methamphetamine Dependence
NCT00859573
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Modafinil
Modafinil
600 mg Modafinil capsule
placebo (cornstarch)
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Modafinil
600 mg Modafinil capsule
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient is agreeable to conditions of study and signs consent form
18 Years
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
California Pacific Medical Center Research Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Gantt Galloway, PharmD
Scientist
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gantt Galloway, PharmD
Role: PRINCIPAL_INVESTIGATOR
California Pacific Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
New Leaf Treatment Center
Lafayette, California, United States
CPMC Research Institute, St.Luke's Hospital
San Francisco, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CPMC-APRL-8B
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.